Condition: Nodular Basal Cell Carcinoma · Sponsor: Feldan Therapeutics
The goal of this clinical trial is to determine safety, tolerability, pharmacokinetics, preliminary efficacy, and Maximum Tolerable Dose (MTD), of intralesional FLD-103 when administered to subjects with Basal Cell Carcinoma (BCC). The main questions it aims to answer are: * Is FLD-103 safe and well tolerated? * What is a safe dose of FLD-103 for future studies? * How much FLD-103 enters the bloodstream and how long does it take to be cleared from the body? * Does FLD-103 reduce the size of the tumor? Participants will: * Receive either a Single Ascending Dose (SAD) of FLD-103 or Multiple Ascending Doses (MAD) of FLD-103 once weekly for four (4) weeks. * Visit the clinic a day after receiving a dose and once weekly for four (4) weeks after that for checkups and tests.
This description comes directly from the study's public registry record.
Catherine Lippé · 1 581-397-8597 · clippe@feldan.com
Always discuss trial participation with your own doctor first.
| Equity Medical | Bowling Green, Kentucky, United States | Recruiting |
| Equity Medical | New York, New York, United States | Not Yet Recruiting |
| Woden Dermatology | Phillip, Australian Capital Territory, Australia | Recruiting |
| Novatrials | Charlestown, New South Wales, Australia | Recruiting |
| Scientia Clinical Research | Randwick, New South Wales, Australia | Recruiting |
| Innovate Clinical Research | Waitara, New South Wales, Australia | Recruiting |
| FNQH Cairns Skin Cancer Clinic | Westcourt, Queensland, Australia | Recruiting |
| Translational Research Institute | Woolloongabba, Queensland, Australia | Recruiting |
| Veracity Clinical Research | Woolloongabba, Queensland, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07670858